全链条打击！多部门运用追溯码查处倒卖“回流药”等问题

Core Viewpoint - The National Medical Insurance Administration, in collaboration with various government departments, is conducting a nationwide special rectification campaign to address prominent issues in medical insurance fund management, focusing on the illegal trade of "returned drugs" [1][2]. Group 1: Regulatory Actions - A special rectification campaign has been launched to investigate the illegal sale of "returned drugs" through the use of drug traceability codes as a key tool [1]. - The campaign has already completed its first phase of verification, resulting in the identification and prosecution of several cases involving the illegal trade of "returned drugs" [1]. - Starting from July 1, 2023, designated medical institutions are required to scan drugs before settling medical insurance fund payments [2]. Group 2: Drug Safety Concerns - The illegal trade of "returned drugs" not only jeopardizes the safety of medical insurance funds but also poses significant risks to public health, as some of these drugs may be expired or improperly stored [2]. - The National Medical Insurance Administration emphasizes that pharmacies have a responsibility to rigorously verify the sources of the drugs they purchase [2]. Group 3: Traceability and Compliance - As of now, a total of 39.885 billion drug traceability codes have been collected since the nationwide implementation of drug traceability code collection began in 2024 [1]. - The public consensus on "verifying codes before buying drugs and scanning codes before selling drugs" has largely been established, with approximately 5 million people checking drug authenticity daily [1]. - Pharmacies are encouraged to use the National Medical Insurance Service Platform App to verify the legitimacy of drugs and avoid engaging in the trade of "returned drugs" [3].